JP2015504893A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015504893A5 JP2015504893A5 JP2014551703A JP2014551703A JP2015504893A5 JP 2015504893 A5 JP2015504893 A5 JP 2015504893A5 JP 2014551703 A JP2014551703 A JP 2014551703A JP 2014551703 A JP2014551703 A JP 2014551703A JP 2015504893 A5 JP2015504893 A5 JP 2015504893A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence number
- group
- polypeptide
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 40
- 229920001184 polypeptide Polymers 0.000 claims 35
- 102000004196 processed proteins & peptides Human genes 0.000 claims 35
- 125000000217 alkyl group Chemical group 0.000 claims 17
- 125000003118 aryl group Chemical group 0.000 claims 10
- 125000000623 heterocyclic group Chemical group 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 125000002947 alkylene group Chemical group 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- 150000002431 hydrogen Chemical class 0.000 claims 8
- 125000005647 linker group Chemical group 0.000 claims 8
- 125000001188 haloalkyl group Chemical group 0.000 claims 6
- 125000004452 carbocyclyl group Chemical group 0.000 claims 5
- 239000012636 effector Substances 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 125000004474 heteroalkylene group Chemical group 0.000 claims 3
- 229910052740 iodine Inorganic materials 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 229910052698 phosphorus Inorganic materials 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 231100000765 toxin Toxicity 0.000 claims 2
- 125000006832 (C1-C10) alkylene group Chemical group 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108091023037 Aptamer Proteins 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 229960002964 adalimumab Drugs 0.000 claims 1
- 125000005275 alkylenearyl group Chemical group 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 125000000732 arylene group Chemical group 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 229940127121 immunoconjugate Drugs 0.000 claims 1
- 229960000598 infliximab Drugs 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229960005027 natalizumab Drugs 0.000 claims 1
- 229960000470 omalizumab Drugs 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 229960000402 palivizumab Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 229940076376 protein agonist Drugs 0.000 claims 1
- 229940076372 protein antagonist Drugs 0.000 claims 1
- 229960003876 ranibizumab Drugs 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 0 CC(C)C(C1(*)N(*)C=*1)=C Chemical compound CC(C)C(C1(*)N(*)C=*1)=C 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261584675P | 2012-01-09 | 2012-01-09 | |
| US61/584,675 | 2012-01-09 | ||
| PCT/IB2013/050131 WO2013105013A1 (en) | 2012-01-09 | 2013-01-07 | Mutant antibodies and conjugation thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015504893A JP2015504893A (ja) | 2015-02-16 |
| JP2015504893A5 true JP2015504893A5 (cg-RX-API-DMAC7.html) | 2016-02-25 |
| JP6413127B2 JP6413127B2 (ja) | 2018-10-31 |
Family
ID=47678955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014551703A Active JP6413127B2 (ja) | 2012-01-09 | 2013-01-07 | 変異抗体およびそのコンジュゲーション |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20130323234A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3447071A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6413127B2 (cg-RX-API-DMAC7.html) |
| AR (1) | AR090410A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2863216C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2700398T3 (cg-RX-API-DMAC7.html) |
| TW (1) | TW201341401A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013105013A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2890256A1 (en) | 2012-11-07 | 2014-05-15 | Pfizer Inc. | Anti-il-13 receptor alpha 2 antibodies and antibody-drug conjugates |
| US9260478B2 (en) * | 2014-04-04 | 2016-02-16 | Shanghui Hu | Potent and efficient cytotoxic peptides and antibody-drug conjugates thereof and their synthesis |
| US11197934B2 (en) * | 2015-09-17 | 2021-12-14 | The Scripps Research Institute | Dual variable domain immunoconjugates and uses thereof |
| CN109843327B (zh) | 2016-07-07 | 2022-05-13 | 小利兰·斯坦福大学托管委员会 | 抗体佐剂缀合物 |
| WO2020028832A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| AU2020241686A1 (en) | 2019-03-15 | 2021-11-04 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting HER2 |
| US20220347312A1 (en) * | 2019-09-04 | 2022-11-03 | Bolt Biotherapeutics, Inc. | Immunoconjugate Synthesis Method |
| CN112307622B (zh) * | 2020-10-30 | 2024-05-17 | 中国兵器科学研究院 | 一种用于计算机生成兵力的自主规划系统及规划方法 |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| JP2024525608A (ja) | 2021-07-09 | 2024-07-12 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体および製剤 |
| AU2022377070A1 (en) * | 2021-11-01 | 2024-04-11 | Dyne Therapeutics, Inc. | Muscle targeting complexes for treating dystrophinopathies |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US7217845B2 (en) * | 2002-11-25 | 2007-05-15 | Sun Bio, Inc. | Bifunctional polyethylene glycol derivatives |
| EP2100619B1 (en) * | 2003-02-20 | 2014-02-12 | Seattle Genetics, Inc. | Anti-CD70 antibody-drug conjugates and their use for the treatment of immune disorders |
| MXPA06001634A (es) * | 2003-08-13 | 2006-04-28 | Pfizer Prod Inc | Anticuerpos humanos modificados igf-1r. |
| CA2594356C (en) * | 2005-01-05 | 2018-07-17 | F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. | Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions |
| JP5167473B2 (ja) | 2005-03-03 | 2013-03-21 | コヴェックス・テクノロジーズ・アイルランド・リミテッド | 抗血管新生化合物 |
| WO2008020827A2 (en) * | 2005-08-01 | 2008-02-21 | Biogen Idec Ma Inc. | Altered polypeptides, immunoconjugates thereof, and methods related thereto |
| UA94060C2 (ru) | 2005-09-07 | 2011-04-11 | Эмджен Фримонт Инк. | Моноклональное антитело, которое специфически связывает alk-1 |
| DK2089425T3 (da) | 2006-11-10 | 2011-10-10 | Covx Technologies Ireland Ltd | Antiangiogene forbindelser |
| US20090098130A1 (en) | 2007-01-05 | 2009-04-16 | Bradshaw Curt W | Glucagon-like protein-1 receptor (glp-1r) agonist compounds |
| US8293714B2 (en) * | 2008-05-05 | 2012-10-23 | Covx Technology Ireland, Ltd. | Anti-angiogenic compounds |
| AU2010336029B2 (en) * | 2009-12-23 | 2011-10-13 | Avipep Pty Ltd | Immuno-conjugates and methods for producing them 2 |
| CA2804185C (en) * | 2010-07-12 | 2017-03-21 | Covx Technologies Ireland Limited | Multifunctional antibody conjugates |
| EP2780039B9 (en) | 2011-11-17 | 2018-04-18 | Pfizer Inc | Cytotoxic peptides and antibody drug conjugates thereof |
-
2013
- 2013-01-07 TW TW102100422A patent/TW201341401A/zh unknown
- 2013-01-07 JP JP2014551703A patent/JP6413127B2/ja active Active
- 2013-01-07 CA CA2863216A patent/CA2863216C/en active Active
- 2013-01-07 WO PCT/IB2013/050131 patent/WO2013105013A1/en not_active Ceased
- 2013-01-07 EP EP18192573.6A patent/EP3447071A1/en active Pending
- 2013-01-07 ES ES13703151T patent/ES2700398T3/es active Active
- 2013-01-07 AR ARP130100061A patent/AR090410A1/es unknown
- 2013-01-07 US US13/736,029 patent/US20130323234A1/en not_active Abandoned
- 2013-01-07 EP EP13703151.4A patent/EP2802355B1/en active Active
-
2020
- 2020-06-09 US US16/896,930 patent/US11780935B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015504893A5 (cg-RX-API-DMAC7.html) | ||
| US11766482B2 (en) | In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use | |
| AU2024202618A1 (en) | Bicyclic peptide ligands specific for EphA2 | |
| JP6787795B2 (ja) | 抗Ａｘｌ抗体 | |
| EP4001307A1 (en) | Antibodies against il-1 beta | |
| WO2022031871A4 (en) | Compositions and methods related to il27 receptor binding | |
| JP2019511201A5 (cg-RX-API-DMAC7.html) | ||
| CN106414498A (zh) | TNF α的结合成员 | |
| JP2022553826A (ja) | 二重ｉｌ－２ｒおよびｉｌ－７ｒ結合化合物 | |
| US20220177597A1 (en) | Anti-CD98hc VNARs for Crossing the Blood Brain Barrier and Type IV VNAR Libraries | |
| CN107148281A (zh) | 结合cxcr5的抗原结合蛋白 | |
| CN112638946A (zh) | 抗il1rap抗体组合物 | |
| US20210395381A1 (en) | Tfr-specific binding moieties and transcytosis method to select vnars that cross cellular barriers | |
| JP2010501164A5 (cg-RX-API-DMAC7.html) | ||
| Wu et al. | Identification of a novel peptide that blocks basic fibroblast growth factor-mediated cell proliferation | |
| JP2019506140A5 (cg-RX-API-DMAC7.html) | ||
| AU2016208161A1 (en) | IL-17A-binding polypeptides | |
| JP2025026839A5 (cg-RX-API-DMAC7.html) | ||
| US20240294638A1 (en) | Anti-nkg2a antibodies and compositions | |
| WO2023219147A1 (ja) | Ｃｃｒ８検出用新規抗ｃｃｒ８抗体 | |
| JP2015520172A5 (cg-RX-API-DMAC7.html) | ||
| JP2017522864A (ja) | 新規ポリペプチド | |
| WO2017149311A1 (en) | Evasins for use in therapy and diagnostics | |
| US11807688B2 (en) | Anti-AXL antibodies and compositions | |
| JPWO2020159754A5 (cg-RX-API-DMAC7.html) |